Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPS-003
- Development stage
- Preclinical
- Lead developer
- Cellontech
- Administration
- Subcutaneous
01
Overview
DPS-003 is a preclinical-stage dermal filler candidate developed by Cellontech for aesthetic indications, such as the correction of facial wrinkles and soft tissue augmentation. As part of Cellontech's Dermal Pro-System (DPS) pipeline, DPS-003 is characterized as a long-lasting filler designed to provide sustained structural support and tissue volume restoration. The developer, Cellontech, specializes in regenerative medicine and atelocollagen-based biomaterials, suggesting that DPS-003 likely utilizes a biocompatible scaffold to integrate with host tissue and provide durable aesthetic results. It is currently in the early stages of development, following the company's established aesthetic products like TheraFill.
Beyond the preview
Go deeper on DPS-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPS-003.